105 related articles for article (PubMed ID: 20978276)
1. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.
Bedikian AY; Silverman JA; Papadopoulos NE; Kim KB; Hagey AE; Vardeleon A; Hwu WJ; Homsi J; Davies M; Hwu P
J Clin Pharmacol; 2011 Aug; 51(8):1205-12. PubMed ID: 20978276
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
[TBL] [Abstract][Full Text] [Related]
3. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.
Deitcher OR; Glaspy J; Gonzalez R; Sato T; Bedikian AY; Segarini K; Silverman J; Deitcher SR
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):197-202. PubMed ID: 24417913
[TBL] [Abstract][Full Text] [Related]
4. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
5. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.
Shah NN; Cole DE; Lester-McCully CM; Wayne AS; Warren KE; Widemann BC
Invest New Drugs; 2016 Feb; 34(1):61-5. PubMed ID: 26661090
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Silverman JA; Reynolds L; Deitcher SR
J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
[TBL] [Abstract][Full Text] [Related]
8. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
Shah NN; Merchant MS; Cole DE; Jayaprakash N; Bernstein D; Delbrook C; Richards K; Widemann BC; Wayne AS
Pediatr Blood Cancer; 2016 Jun; 63(6):997-1005. PubMed ID: 26891067
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
[TBL] [Abstract][Full Text] [Related]
10. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.
Rodriguez MA; Pytlik R; Kozak T; Chhanabhai M; Gascoyne R; Lu B; Deitcher SR; Winter JN;
Cancer; 2009 Aug; 115(15):3475-82. PubMed ID: 19536896
[TBL] [Abstract][Full Text] [Related]
11. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
Silverman JA; Deitcher SR
Cancer Chemother Pharmacol; 2013 Mar; 71(3):555-64. PubMed ID: 23212117
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.
Douer D
Oncologist; 2016 Jul; 21(7):840-7. PubMed ID: 27328933
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs.
Zhong J; Mao W; Shi R; Jiang P; Wang Q; Zhu R; Wang T; Ma Y
Cancer Chemother Pharmacol; 2014 Mar; 73(3):459-66. PubMed ID: 24362508
[TBL] [Abstract][Full Text] [Related]
14. Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia.
Harrison TS; Lyseng-Williamson KA
BioDrugs; 2013 Feb; 27(1):69-74. PubMed ID: 23329395
[TBL] [Abstract][Full Text] [Related]
15. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
[TBL] [Abstract][Full Text] [Related]
16. Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma.
Roveri M; Pfohl A; Jaaks P; Alijaj N; Leroux JC; Luciani P; Bernasconi M
Nanomedicine (Lond); 2017 May; 12(10):1135-1151. PubMed ID: 28447920
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma.
Yang F; Jiang M; Lu M; Hu P; Wang H; Jiang J
Front Pharmacol; 2018; 9():991. PubMed ID: 30210349
[No Abstract] [Full Text] [Related]
18. [Transdermal and lymph targeting transfersomes of vincristine].
Lu Y; Hou SX; Zhang LK; Li Y; He JY; Guo DD
Yao Xue Xue Bao; 2007 Oct; 42(10):1097-101. PubMed ID: 18229621
[TBL] [Abstract][Full Text] [Related]
19. Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction.
Briasoulis E; Karavasilis V; Tzamakou E; Piperidou C; Soulti K; Pavlidis N
Anticancer Drugs; 2006 Nov; 17(10):1219-22. PubMed ID: 17075322
[TBL] [Abstract][Full Text] [Related]
20. Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC).
Repetto L; Grimaldi A; Ardizzoni A; Sertoli MR; Rosso R
Chemioterapia; 1987 Feb; 6(1):63-5. PubMed ID: 3829137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]